Phase 2 clinical trial results for moxidectin in scabies to be presented at the 2026 AAD Innovation Academy

Melbourne, Australia, 15 July 2026 – Atticus Medical Pty Ltd and Medicines Development for Global Health today announced that Phase 2 clinical trial results for moxidectin in scabies will be presented at the upcoming American Academy of Dermatology (AAD) Innovation Academy Conference, taking place from 16-19 July 2026 in New York. Atticus Medical is advancing the development of moxidectin as a single-dose oral treatment designed to simplify the management of scabies and improve health outcomes.

‍

Oral Presentation Title: Moxidectin for Scabies: A Phase 2, placebo-controlled,double-blind, randomized, dose ranging, efficacy and safety study of orallyadministered moxidectin in adults with scabies

Presenter: Vidya Uprety, Principal Clinical Project Manager, Medicines Development for Global Health

Date / Time: Thursday 16 July | 13:00-16:45 ET

Location: Mercury Ballroom, New York Hilton Midtown

Moxidectin is in development and not approved for treatment of scabies infestation in any country or region.

-END

‍

‍

About Atticus Medical Pty Ltd

Atticus Medical is a Melbourne-based specialty biopharmaceutical company, delivering exceptional science and compassionate solutions that help patients with infectious diseases reclaim their lives.

‍

For further information, please contact:

George Rugarabamu, Executive Manager, Corporate Development

Atticus Medical Pty Ltd

grugarabamu at atticusmed dot com

www.atticusmed.com

‍